Knowledge Base Wiki

Search for LIMS content across all our Wiki Knowledge Bases.

Type a search term to find related articles by LIMS subject matter experts gathered from the most trusted and dynamic collaboration tools in the laboratory informatics industry.

Add links

Aumolertinib
Clinical data
Trade namesAmeile
Other namesAlmonertinib; HS-10296
ATC code
Legal status
Legal status
  • CN: Rx-only
Identifiers
  • N-[5-[[4-(1-Cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC30H35N7O2
Molar mass525.657 g·mol−1
3D model (JSmol)
  • CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC
  • InChI=1S/C30H35N7O2/c1-6-29(38)32-24-17-25(28(39-5)18-27(24)36(4)16-15-35(2)3)34-30-31-14-13-23(33-30)22-19-37(20-11-12-20)26-10-8-7-9-21(22)26/h6-10,13-14,17-20H,1,11-12,15-16H2,2-5H3,(H,32,38)(H,31,33,34)
  • Key:DOEOECWDNSEFDN-UHFFFAOYSA-N

Aumolertinib (trade name Ameile) is a pharmaceutical drug for the treatment of cancer.[1] It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).[2]

In China, aumolertinib is approved for the treatment of patients with EGFR T790M mutation—positive non-small-cell lung cancer (NSCLC) who have progressed on or after other EGFR TKI therapy.[3][4]

References

  1. ^ Shirley M, Keam SJ (April 2022). "Aumolertinib: A Review in Non-Small Cell Lung Cancer". Drugs. 82 (5): 577–584. doi:10.1007/s40265-022-01695-2. PMID 35305259.
  2. ^ Johnson ML, Miller VA, Patel S, Zhao Y, Cheng L, Ali SM, et al. "Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE)". Journal of Clinical Oncology. 41 (16). doi:10.1200/JCO.2023.41.16_suppl.TPS9153.
  3. ^ "Almonertinib Approved in China for EGFR T79M+ NSCLC". onclive.com. 19 March 2020.
  4. ^ Lu S, Wang Q, Zhang G, Dong X, Yang CT, Song Y, et al. (March 2022). "Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial". Journal of Thoracic Oncology. 17 (3): 411–422. doi:10.1016/j.jtho.2021.10.024. PMID 34801749.


source: https://en.wikipedia.org/wiki/Aumolertinib